Core Insights - ST诺泰 has received approval from the drug regulatory authority for two injectable drugs: Acetate Cetrorelix and Agomelatine, marking a significant milestone in the company's product pipeline [1][2] Group 1: Product Approval - Acetate Cetrorelix is a third-generation GnRH antagonist that offers unique clinical advantages in assisted reproductive technology compared to other similar drugs, such as GnRH agonists and other antagonists like Ganirelix [1] - Acetate Cetrorelix demonstrates superior onset speed, safety (prevention of OHSS), shorter treatment cycles, and better patient tolerance compared to GnRH agonists, and has milder injection reactions compared to other antagonists [1] - Agomelatine is a novel antidepressant with a unique dual mechanism of action, distinguishing it from common antidepressants like SSRIs and SNRIs, and is the only antidepressant that improves sleep quickly without affecting daytime functioning [1] Group 2: Market Position and Strategic Expansion - The approval of these two drugs represents ST诺泰's proactive expansion into reproductive health and mental health sectors, building on its existing pipeline of antiviral, cardiovascular, and immune-modulating agents [2] - The company's strategy aligns with national policies promoting childcare subsidies and the inclusion of assisted reproduction in health insurance, providing strong support for patient services and contributing to the high-quality development of the national population [2]